key: cord-0705547-iwas54qx
authors: Bassatne, Aya; Basbous, Maya; Chakhtoura, Marlene; Zein, Ola El; Rahme, Maya; Fuleihan, Ghada El-Hajj
title: The link between COVID-19 and VItamin D (VIVID): a systematic review and meta-analysis
date: 2021-03-24
journal: Metabolism
DOI: 10.1016/j.metabol.2021.154753
sha: b79caa6e11ce47ccc4af534379cda227bbb8c91a
doc_id: 705547
cord_uid: iwas54qx

BACKGROUND: Disease severity and mortality rates due to COVID-19 infection are greater in the elderly and chronically ill patients, populations at high risk for vitamin D deficiency. Vitamin D plays an important role in immune function and inflammation. This systematic review and meta-analysis assesses the impact of vitamin D status and supplementation on COVID-19 related mortality and health outcomes. METHODS: We searched four databases until December 18th 2020, and trial registries until January 20th 2021. Two reviewers screened the studies, collected data, assessed the risk of bias, and graded the evidence for each outcome across studies, independently and in duplicate. Pre-specified outcomes of interest were mortality, ICU admission, invasive and non-invasive ventilation, hospitalization, time of hospital stay, disease severity and SARS-CoV-2 positivity. We only included data from peer-reviewed articles in our primary analyses. RESULTS: We identified 31 peer-reviewed observational studies. In our primary analysis, there was a positive trend between serum 25(OH)D level < 20 ng/ml and an increased risk of mortality, ICU admission, invasive ventilation, non-invasive ventilation or SARS-CoV-2 positivity. However, these associations were not statistically significant. Mean 25(OH)D levels was 5.9 ng/ml (95%CI [−9.5, −2.3]) significantly lower in COVID-19 positive, compared to negative patients. The certainty of the evidence was very low. We identified 32 clinical trial protocols, but only three have published results to-date. The trials administer vitamin D doses of 357 to 60,000 IU/d, from one week to 12 months. Eight megatrials investigate the efficacy of vitamin D in outpatient populations. A pilot trial revealed a significant decrease in ICU admission with calcifediol, compared to placebo (OR = 0.003), but the certainty of the evidence was unclear. Another small trial showed that supplementation with cholecalciferol, 60,000 IU/d, decreased fibrinogen levels, but did not have an effect on D-dimer, procalcitonin and CRP levels, compared to placebo. The third trial did not find any effect of vitamin D supplementation on COVID-19 related health outcomes. CONCLUSION: While the available evidence to-date, from largely poor-quality observational studies, may be viewed as showing a trend for an association between low serum 25(OH)D levels and COVID-19 related health outcomes, this relationship was not found to be statistically significant. Calcifediol supplementation may have a protective effect on COVID-19 related ICU admissions. The current use of high doses of vitamin D in COVID-19 patients is not based on solid evidence. It awaits results from ongoing trials to determine the efficacy, desirable doses, and safety, of vitamin D supplementation to prevent and treat COVID-19 related health outcomes.

Endocrinologists (AACE), European Calcified Tissue Society (ECTS) and National Osteoporosis Foundation (NOF), recommended a daily dose of 400-1,000 IU vitamin D in the COVID-19 pandemic, especially during home isolation for bone protection (27) . These societies do not however recommend supplementation for COVID-19 prevention.

We therefore implemented a systematic review and meta-analysis of observational studies assessing the relationship between serum 25(OH)D levels and COVID-19 related mortality and other health outcomes, to fill this major knowledge gap. We also systematically collected information on vitamin D randomized trials, including on-going ones, to evaluate the body of the upcoming evidence on the effects of vitamin D supplementation on COVID-19 related outcomes. We hypothesized that vitamin D deficiency is associated with an increased risk of COVID-1 9 related health outcomes and that vitamin D supplementation would decrease these risks.

The protocol of this systematic review and meta-analysis is available online on PROSPERO; registration number CRD42020203960.

The population of interest consists of adult patients with SARS, MERS or COVID-19 infection. The exposure is vitamin D status in observational studies, and vitamin D in any form and dose, as the intervention in clinical trials.

Literature search: we conducted a comprehensive search using four databases: Medline (OVID), Embase.com, CINAHL (EBSCO), and Cochrane until December 18 th , 2020, with no limit on language (Appendix A). We used MESH terms and keywords relevant to vitamin D and COVID-19. We planned to include SARS and MERS viruses to detect any indirect evidence in case of scarcity of studies on COVID-19. We have limited the terms related to the Coronaviridae family to the year of the first outbreak (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) (2017) (2018) (2019) (2020) . The search strategy was reviewed and verified by our head medical librarian (OEZ). We also added any publications brought to our attention by experts and senior authors, or by manual review of references in the included papers. We searched the grey literature including MedRxiv, the Endocrine Society, ASBMR, Centers for Disease Control and Prevention, International Osteoporosis Foundation, and WHO websites (28, 29) . We translated all abstracts written in a language other than English to assess their eligibility. Trial registries: we searched ClinicalTrials.gov and the WHO primary trial registries, namely the EU Clinical Trials Register (EU-CTR), Australian New Zealand Clinical Trials Registry (ANZCTR), and Iranian Registry of Clinical Trials (IRCT), up until January 20 th 2021, for ongoing trials on vitamin D and COVID-19 (30) .

The search strategy identified 6,300 citations. Following duplicate removal, we screened a total of 5,378 citations, of which 223 articles were potentially eligible. We retained 36 articles after excluding 187 articles for the presence of one or more exclusion criteria. Reasons for excluding these records are presented in Appendix B. After screening the grey literature and the references of the 187 studies, and screening three articles based on the opinion of experts and senior authors, we identified 7 additional eligible articles (Fig. A) . The final yield included 43 original articles. Nine studies were not peer-reviewed and therefore excluded (35) (36) (37) (38) (39) (40) (41) (42) (43) . We extracted data from 31 peer-reviewed observational studies, and 3 RCTs, that reported on vitamin D status and COVID-19 infection and/or health related outcomes. We did not identify any eligible data on MERS or SARS. Table A describes the characteristics of the 31 included observational studies ordered by outcome severity . These studies reported on mortality from COVID-19 (n=20), ICU admission (n=5), length of ICU stay (n=1), invasive ventilation (n=7), non-invasive ventilation (n=4), hospitalization (n=3), length of hospital stay (n=5), disease severity (n=12), pneumonia (n=1), multi-organ damage (n=1), acute kidney injury (n=1), ARDS (n=5), SARS-CoV-2 positivity (n=4), and 25(OH)D levels (n=7). The included studies were conducted in the United States (n=3), Europe (n=13), Asia (n=8) and the Middle East (n=7). COVID-19 patients were assessed in the inpatient setting in 24 studies (44-47, 49-64, 66-68, 70) , in the outpatient setting in 4 studies (71) (72) (73) (74) and in both the in and outpatient setting in 3 studies (48, 65, 69) . The mean age of patients ranged between 42 and 81 years. The percentage of females ranged between 20% and 67%. Participants had multiple comorbidities, most commonly hypertension (25-80%), cardiovascular disease (11-62%) and diabetes (10-44%). Timing for blood withdrawal of serum 25(OH)D was not mentioned in 12 studies. It occurred 10 years prior to study conduct in 2 studies, within 1 year of study conduct in 1 study, within 6 months or 12 weeks prior to admission in 1 study each, or at the time of testing for COVID-19 status or admission to the hospital in COVID-19 positive cases in 10 studies. It was done within 48 hours, 7 days of hospital admission, or 7 weeks, or three months, post-discharge, in one study for each time frame. Mean serum 25(OH)D levels ranged between 11 and 35 ng/ml, BMI was between 23.5 and 32 kg/m 2 , and the proportion of subjects with a serum 25(OH)D <20 ng/ml varied between 13 and 82%. Twenty-three studies specified the type of 25(OH)D assay used, and only 3 used liquid chromatography mass spectroscopy. Fourteen studies were cross-sectional (44-46, 49, 52-55, 59-62, 68, 71) , four were case-control (65, 69, 70, 72) , eleven were cohort (48, 50, 51, 56-58, 63, 64, 66, 73, 74) , and two were a combination of cross-sectional and case-control designs (47, 67) . Appendix C.1 provides the detailed assessment for each of the risk-of-bias domains.

Twenty studies reported on the association between vitamin D status and mortality (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (Table A) . Of these, 13 were cross sectional studies (44-47, 49, 52-55, 59-62) while 7 were J o u r n a l P r e -p r o o f Journal Pre-proof cohort studies (48, 50, 51, (56) (57) (58) 63) . The sample size ranged from 21 to 984 individuals/study,  mean age ranged between 42 and 88 years, and the proportion of female participants varied  between 20 and 58%. Six studies reported data on different 25(OH)D cutoffs (10, 12, 15.2, 25 and 30 ng/ml) (46, 49, 50, 55, 57, 63) . Of these, five reported a significant increased risk of mortality in vitamin D deficient COVID-19 patients (49, 50, 55, 57, 63) . Six studies did not have numerical data on mortality by vitamin D status (48, 54, (58) (59) (60) (61) . The study of Maghbooli et al. demonstrated a two folds increase in mortality risk in patients with 25(OH)D levels <30 ng/ml. However, we did not include it in the analysis because of the discrepancy between reported results in the text and figures, unavailable original data despite contacting the authors, and the subsequent Editors' statement post-publication (44, 75) . Seven studies identified low vitamin D levels as 25(OH)D levels <20 ng/ml and were therefore eligible for the primary analysis (45, 47, 51-53, 56, 62) . The individual results of these seven studies are summarized in Table B .

Combining data from these seven studies (N=945) revealed a trend between low serum 25(OH)D levels and the risk of mortality (RR= 2.1, 95% CI [0.9-4.8]; I 2 = 76%) (Fig. B.1 ). Serum 25(OH)D levels were measured on admission in three studies (45, 52, 62) , within 48 hours of admission in one study (51) , and within 7 days in one study (47) . The certainty of evidence for this outcome was very low because all studies assessing mortality from COVID-19 were observational of poor quality, the results were inconsistent and imprecise, as shown by the high heterogeneity (I 2 =76%) and the wide confidence interval (Table C, Appendix C.1) .

Three studies had available data for mortality using a higher serum 25(OH)D cutoff (30 ng/ml) (45, 53, 63) . Combining their data (N=373), showed a significant increased risk of mortality in COVID-19 patients with 25(OH)D<30 ng/ml (RR=3.1, 95% CI [1.4-6.8]; I 2 =0%) (Appendix D.1) (45, 53, 63).

Five studies assessed the risk of ICU admission in hospitalized COVID-19 patients with low 25(OH)D levels (44, 51, 52, 56, 64) (Table A) . Two studies consisted of cross-sectional designs (44, 52) , while three were cohorts (51, 56, 64) . The sample size ranged from 43 to 235 individuals. Mean age was between 46 and 74 years, and the proportion of female participants varied between 38% and 46%.

We included three studies in our main analysis (51, 52, 56) . Table B provides a summary of the results of these individual studies. Pooling data from these studies (N=480) revealed a trend for an increased risk of ICU admission in COVID-19 patients with 25(OH)D levels<20 ng/ml (RR=4.9, 95% CI [0.5-44.3], I 2 =85%) (Fig B. 2). 25 (OH)D levels were measured during admission in two studies (51, 52) and the timing of measurements was not mentioned in the third study (56) . The certainty of evidence of this outcome was very low because all studies were observational, of poor quality, and the results were both very inconsistent and imprecise ( 

Seven studies assessed the risk of invasive ventilation in hospitalized COVID-19 patients by vitamin D status (44, 47, 48, 52, 57, 61, 63) . Three were cohort studies (48, 57, 63) , and four were of cross-sectional design (44, 47, 52, 61) . The sample size ranged between 30 and 984. The median age varied between 58 and 76 years, and the proportion of female participants was between 20 and 58% (Table A) .

Three studies used different 25(OH)D levels cutoffs (12, 15.2 and 30 ng/ml) (44, 48, 57) . Only one of the three reported a significant increased risk of invasive mechanical ventilation in COVID-19 patients with 25(OH)D<12 ng/ml (48) . Two studies did not report numerical data for invasive mechanical ventilation by 25(OH)D level status (61, 63) . Pooling data from the remaining two studies (47, 52) , showed a trend for an increase in invasive ventilation requirement in patients with 25(OH)D levels <20 ng/ml (RR= 1.3, 95% CI [0.6-2.8]; I 2 = 0%) (Fig. B. 3). Serum 25(OH)D levels were measured on admission (52) , and within 7 days of admission (47) . The certainty of evidence of this outcome was very low because both studies were observational of poor quality, and the results were imprecise (Table C, Appendix C.1).

Four studies assessed the risk of non-invasive ventilation, using high flow oxygen masks or nasal cannula, in hospitalized COVID-19 patients by vitamin D status (46) (47) (48) 52) (Table A) . Three were cross-sectional studies (46, 47, 52) and one was a cohort design (48) . The sample size ranged between 50 and 197. The mean age varied between 58 and 81 years, and the proportion of women was between 38 and 58% (Table A) . Two studies reported a significant increased risk of non-invasive ventilation in COVID-19 patients with vitamin D 25(OH)D level < 12 ng/ml. We excluded them from our primary analysis due to the lower 25(OH)D cutoff (46, 48) . Pooling data from the remaining two studies (47, 52) , showed no association between noninvasive ventilation requirement and 25(OH)D levels <20 ng/ml (RR=1.1, 95% CI [0.3-3.8]; I 2 =23%) (Fig. B.4 ). The certainty of evidence of this outcome was very low due to the poor quality of both observational studies and the imprecise results (Table C, Appendix C.1).

Three studies assessed the risk of hospitalization from COVID-19 disease in patients with low 25(OH)D levels (48, 65, 66) . One was a case-control study (65) and two were cohort studies (48, 66) . The sample size ranged between 80 and 7,807. The median age was 60 years in 1 study (48) , and the percentage of women varied between 49 and 60%. We did not conduct a metaanalysis for this outcome because of heterogeneity in the cutoffs used for serum 25(OH)D levels. compared to those with desirable vitamin D status, but this difference was not statistically significant (p=0.051) (66).

Five studies assessed the length of hospital stay in COVID-19 patients with low 25(OH)D levels (44, 52, 54, 61, 63) . One was a cohort study (63) , and four were cross-sectional (44, 52, 54, 61) . Two studies did not report the length of hospital stay by 25(OH)D level status (54, 61) . Hernandez et al. reported a significantly higher length of hospital stay in COVID-19 patients with serum 25(OH)D <20 ng/ml (median=12 days (IQR 8-17)) as compared to those with desirable vitamin D status (median=8 days (IQR 6-14)) (p=0.013) (52) . Two studies had available data for length of hospital stay using a higher serum 25(OH)D cutoff (30 ng/ml) (44, 63) . Combining their data (N=379), showed no significant difference in length of hospital stay between COVID-19 patients with 25(OH)D<30 ng/ml compared to those with more desirable levels (MD=0, 95%CI [-0.97, 0.97]; I 2 =0%) (Appendix D.2) (44, 63).

Twelve studies assessed the risk of severe COVID-19 disease by vitamin D status (44, 45, 49-51, 53, 54, 57, 60, 62, 66, 67) . Eight studies were of cross-sectional design, and 4 were cohort studies ( Table A) . The sample size ranged between 30 and 335, age ranged between 42 and 74 years, and 20-61% were women.

The definition of severity and the cutoff for 25(OH)D levels varied between studies; we therefore could not pool results from all studies (Table A) . Two studies defined disease severity as SaO2 <93% or respiratory distress or lung infiltrates more than 50% within 24 to 48 hours or respiratory failure or organ failure (44, 53) . Pooling data from these two studies (N=384), as a sensitivity analysis, showed a trend for an increased COVID-19 disease severity in patients with serum 25(OH)D< 30 ng/ml (RR=3.0, 95% CI [0.19-48.2]; I 2 =77%) (Appendix D.3). Serum 25(OH)D was measured on admission in one study (44) , and timing of measurement was not specified in the other (53).

Four cross-sectional studies and one cohort study assessed the association between Acute Respiratory Distress Syndrome (ARDS) and vitamin D status in patients with COVID-19 infection (44, 49, 52, 57, 68) . Sample size ranged between 30 and 235 individuals, mean age ranged between 49 and 72 years and percent female participants ranged between 20 and 53% ( Table A) . None of these studies had data for 25(OH)D levels <20 ng/ml, therefore a main analysis was not conducted for this outcome.

Two studies had available data for ARDS in patients with 25(OH)D levels< 30 ng/ml (44, 49) . Combining their data revealed no significant increase in the risk of ARDS in COVID-19 patients with low 25(OH)D levels (<30 ng/ml) (Appendix D.4). Vitamin D levels were measured during hospitalization in one study (44) , while the timing of measurements was not mentioned in the other (49).

Four case-control studies assessed the risk of being SARS-CoV-2 positive by PCR in patients with low 25(OH)D levels and presenting for potential symptoms of COVID-19 (65, 67, J o u r n a l P r e -p r o o f Journal Pre-proof 69, 70) . The mean age of participants was 46 and 47 years in 2 studies (69, 70) . The percentage of women participants varied between 60 and 67%.

Three studies defined serum 25(OH)D <20 ng/ml and were therefore included them in a meta-analysis (61, 65, 69) . The individual results of these studies are summarized in Table B . The pooled effect (N=8,448) showed a higher risk of SARS-CoV-2 positivity in patients with low 25(OH)D levels (RR=1.4, 95% CI [0.9-2], I 2 =76%) (Fig. B.5 ). But while timing of blood draw was specified as within a year before COVID testing in one (69), it was not mentioned in the remaining two studies (65, 67) . The certainty of evidence of this outcome was low (Table C) . These studies consisted of two case-control studies of good quality (65, 69) and one case-control study of poor quality (67) . The results were both imprecise and very inconsistent (Table C) .

Two studies had data on 25(OH)D<30 ng/ml (65, 70) . Pooling data from both studies (N=8,209) in a sensitivity analysis showed that 25(OH)D<30 ng/ml was associated with a 1.5 higher risk of COVID-19 positivity compared to vitamin D sufficient patients (RR =1.5, 95% CI [1.3, 1.8], I 2 =0%) (Appendix D.5).

Im et al. did not report a significant difference in serum 25(OH) levels, measured within 7 days of admission, between patient who developed COVID-19 related pneumonia and those who did not (47) . Maghbooli et al. showed no significant association between vitamin D status, measured on admission, and acute kidney injury or multi-organ damage (44) . Vassiliou et al. reported a median of 17 days in ICU in patients with serum 25(OH)D<15.2 ng/ml and 35 in those with levels >15.2 ng/ml, however this difference was not significant (57).

We did not identify any data regarding time on respirators, time to seronegative conversion, time to symptomatic recovery and risk of seropositive conversion in family members.

Seven studies assessed serum 25(OH)D level in patients with COVID-19 infection as compared to those without COVID-19 (46, 67, (70) (71) (72) (73) (74) . Two were cross-sectional studies (46, 71) , three were case-control studies (67, 70, 72) , and two were cohort studies (73, 74) . The sample size ranged from 105 to 4,510. The mean age varied between 42 and 81 years, and the proportion of women was between 46 and 67%.

Two cohort studies were conducted in the same population (73, 74) , the UK biobank, and one study did not provide the standard deviation for the mean 25(OH)D levels (71) . We therefore included only 5 studies in the primary analysis (46, 67, 70, 72, 73) . Combing data from these 5 studies (N=5,266) revealed that serum 25(OH)D level in COVID-19 patients was 5.9 ng/ml lower than that in individuals without COVID-19 (MD -5.9, 95%CI [-9.5, -2.3]; I 2 = 94%) (Fig.  C) . If we were to exclude the study of Baktash et al. from the analysis, because of the lower quality of cross sectional-studies, the mean difference becomes 4.9 ng/ml, and is still significant (data not shown) (46) . Timing on blood draw with relation to COVID testing was 10 years prior in the cohort study (73) , within 7 weeks of PCR in one case control study (72) , and during acute illness in the cross-sectional study (46) . Four studies were of poor quality, while only one was a cohort of good quality (73) (Appendix C.1).

Journal Pre-proof

A pilot study, recently published preliminary data on a subset of patients (76 out of the 1,008 target participants) based on the COVIDIOL trial protocol conducted in Spain (NCT04366908, EudraCT2020-001717-20) (76) . The study was a randomized double blinded controlled trial, in which hospitalized COVID-19 patients received standard care (hydroxychloroquine and azithromycin) alone (N=26) or with calcifediol (N=50). The treatment group received 0.532 mg of calcifediol on admission, 0.266 mg on days 3 and 7, and then weekly. The mean age of participants was 53 ± 10 years, 31% and 46% of the participants were women in the treatment and control groups respectively. Baseline characteristics were similar between treatment groups. Only one out of the 50 patients receiving calcifediol required ICU admission while 50% of those not receiving vitamin D required ICU admission. The OR ratio of ICU admission in patients with calcifediol treatment v/s those with no treatment was 0.03 (95%CI: 0.003-0.25) (76) . The overall risk of bias in this study was uncertain mainly stemming from the unclear description of allocation concealment and blinding of participants (Appendix C.2).

A small (non-registered) trial from India, randomized COVID-19 patients with vitamin D deficiency (25(OH)D<20 ng/ml) to receive either 60,000 IU/d of cholecalciferol (N=16) or placebo (N=24) for 7 days (77). At 7 days if the 25(OH)D serum level did not reach 50 ng/ml, participants in the intervention arm continued the same supplementation for 7 additional days. If serum 25(OH)D exceeded 50ng/ml they were supplemented with 60,000 IU/week. The median age of participants was 50 in the intervention arm and 47 in the placebo arm. Baseline characteristics were similar between treatment groups except for serum calcium levels which were higher in the intervention group. At the 14 days follow up, 62.5% of the participants in the intervention arm became SARS-CoV-2 negative compared to only 20.8% in the control arm. In addition, there was a significant increase in serum 25(OH)D levels (+42.4 v/s +5.1 ng/ml) and a significant decrease in fibrinogen levels (-0.9 v/s -0.04 ng/ml) in the intervention group compared to placebo. However, there was no significant difference in CRP, procalcitonin, ferritin and D-dimer levels (77) . The overall risk of bias in this study was unclear mainly due to the unclear description of sequence generation, allocation concealment, blinding, and selective outcome reporting (Appendix C.2).

A newly published trial from Brazil randomized 240 COVID-19 patients to receive either a single oral dose of vitamin D3 at a dose of 200,000 IU (N=120) or placebo (N=120) (78) . Baseline characteristics were comparable between intervention groups. The mean age of participants was 56 in both arms and 41.2% and 46.6% of participants were women in the intervention and placebo arm respectively. The length of hospital stay was not statistically different between both arms. In addition, supplementation of 200,000 IU of vitamin D3 did not improve COVID-19 related health outcomes such as mortality, ICU admission and need for mechanical ventilation compared to placebo. Although the risk of bias was low in most of the J o u r n a l P r e -p r o o f Journal Pre-proof items assessed, the overall risk of bias in this study was unclear due to the lack of description of the allocation concealment method (Appendix C.2).

We identified 32 trials protocols, including two of the above trials, from the clinicaltrials.gov (n=23) and WHO registries, including the European (n=4) and Iranian registries (n=5) (search current until January 20 th 2021) (Appendix E). Three were expected to be completed in the summer of 2020, an additional four by December 2020. One trial was completed in November 2020, and results have been recently published as discussed above (78) . The remaining studies identified in clinicaltrials.gov are expected to be completed in 2021. The expected completion date was not specified in trials identified in the European and Iranian registers (Appendix E). The on-going trials are being conducted across continents, in the USA, Canada, UK, Argentina, Brazil, Spain, France, Belgium, Switzerland, India, Jordan, and Iran. The Vitamin D formulation is D3 in 22 studies, calcifediol in two studies, and not mentioned in the other 9 protocols. Vitamin D is administered as daily (N=17), weekly (N=4), or in large boluses once or in discrete repeated timings (N=12). The doses range is between a daily equivalent of 357 and 60,000 IU/d. Study duration ranges between one week and 12 months. 26 trials aim to study the effect of vitamin D treatment in COVID-19 patients while 6 studies aim to identify a role in prevention of COVID-19 infection with supplementing healthy patients (n=4) or health care workers (n=2) with vitamin D. Primary outcomes include COVID-19 infection, infection duration, hospitalization, hospital stay, ICU admission, ICU stay, mortality, symptoms severity, symptoms recovery, seronegative conversion, respiratory failure, and laboratory measurements including CRP, Il-6, IL-1, TNFa, 25(OH)D, and serum COVID-19 antibodies levels (Appendix E).

We identified 8 mega-trials with a sample size ranging between 1,008 and 5,440, that span between 2 weeks and 24 weeks of vitamin D supplementation, and doses between 1,000 IU/d and 9,600 IU/d. Of these, four are conducted in outpatient COVID-19 patients and primarily assess the effect of vitamin D on health-related outcomes such as hospitalization, ICU admission and mortality. The other four assess the effect of vitamin D in preventing infection in healthy volunteers (n=2) or health care workers (n=2).

This systematic review and meta-analysis reveals very uncertain evidence for an association between serum 25(OH)D levels <20 ng/ml and risk of mortality, ICU admission, mechanical ventilation, non-invasive ventilation and testing positive for SARS-CoV-2. However, serum 25(OH)D levels were 6 ng/ml lower in COVID-19 patients as compared to those without COVID-19 infection, this difference was significant. Increasing the cutoff of low 25(OH)D levels to 30 ng/ml in our sensitivity analysis, revealed a significantly increased risk of mortality and testing positive for SARS-CoV-2 in patients with such levels. However, there were no associations with risk of disease severity and ARDS, and length of hospital stay. We only identified three completed clinical trials of uncertain quality. A pilot trial was the first to demonstrate that supplementation with calcifediol, a non-traditional form of vitamin D, may improve clinical outcomes specifically ICU admissions in COVID-19 hospitalized patients. The

Journal Pre-proof second small study suggests that supplementation with cholecalciferol may lead to a faster recovery from COVID-19. The third study did not show any effect of vitamin D supplementation on COVID-19 related health outcomes.

The putative protective effects of vitamin D on COVID related health outcomes is stipulated to be mediated by several mechanisms. These include modulating the cytokine storm resulting from activation of the RAS system subsequent to activation of the ACE receptor by the coronavirus, modulating neutrophil activity, maintaining the pulmonary epithelial barrier, and stimulating epithelial repair (79, 80) . This mechanism might lead to the speculated protective role of vitamin D supplementation. This hypothesis is supported by the results of the pilot clinical trial which revealed that supplementation of calcifediol reduced risk of ICU admission from COVID-19 (76) . In our meta-analysis, there was a trend of increased risk of ICU admission with low 25(OH)D levels. The above-described pathophysiology may also explain a potential decrease in other COVID related health outcomes including mortality. However, our findings on mortality in the primary analysis based on seven studies were not significant.

In our meta-analysis of 8,209 patients, patients with serum 25(OH)D levels <30 ng/ml were 1.5 times more likely to test positive for COVID-19 compared to patients with desirable 25(OH)D levels. In addition, the difference in 25(OH)D levels based on COVID-19 positivity might suggest a role for calcitriol, the active metabolite of vitamin D in inhibiting post-entry viral replication in nasal epithelial cells, leading to decreased SARS-CoV-2 viral titers and thus a lower risk of testing positive for COVID-19 in vitamin D replete individuals (81) . These findings are in line with those from previous studies reporting on the increased risk of viral respiratory infections with vitamin D deficiency, and the efficacy of vitamin D supplementation in reducing that risk (13, 21, 82, 83) . In fact, vitamin D's role in immunity is well established (17, 84) .

This systematic review and meta-analysis has several limitations with regards to its conclusions, that stems from the studies themselves, namely the low quality and certainty of the evidence available to-date. Limitations include the scarce evidence provided from published observational studies, and from the heterogeneity in the definition of vitamin D deficiency, and the timing of blood withdrawal in relation to the diagnosis of COVID-19. We identified results from only three randomized controlled trials, and we could only meta-analyze results from few observational studies, which downgrades the level of evidence. Furthermore, only 14 studies adjusted for important confounders of low vitamin D, such as season, age and BMI, comorbidities, known predictors which may have introduced information bias (44, 47, 48, 50, 54, 58, 61, 62, 65-67, 69, 73, 74) . Importantly, we scrutinized the timing of serum 25(OH)D measurement with regards to the timing of assessment of COVID related outcomes, and types of assays used. This is crucial considering the impact of acute illness on serum 25(OH)D levels (85) (86) (87) (88) (89) , and thus the potential for reverse causality in such observational studies. One study assessed the correlation between COVID related health outcomes and vitamin D levels measured within one year prior to the study (69) . Several studies assessed the correlation between vitamin D status and mortality, ICU admission, hospitalization and disease severity, but did not mention the timing of 25(OH)D levels measurement (49, 53, 55, 56, 58-60, 64, 65, 67, 70, 71) . In addition, 25(OH)D levels were measured in acute settings in 12 studies (44-48, 50-52, 54, 57, 62, 68) and more than 2/3 of the studies were conducted in the inpatient COVID-19 patients (44-47, 49-62, 64, 66-68, 70) . Serum 25(OH)D levels in acutely ill patients are usually lower than those of healthy individuals due to inflammation (84) (85) (86) (87) . In fact, 25(OH)D levels may decrease by 40% within the first 24 hours of acute illness (86, 87) . Injection of E.coli lipopolysaccharides induced inflammation in normal volunteers and resulted in an acute decrease in mean serum 25(OH)D

Journal Pre-proof levels by 2.6 ng/ml, as measured by mass spectroscopy, 2-3 hours later (90, 91) . Furthermore, decreased synthesis of vitamin D binding proteins and increased 25(OH)D renal excretion, may play a significant role in regulating vitamin D levels in critically ill patients (88, 89) . Therefore, the low levels measured during the illness reported in the included studies might be due to the acute illness. Interestingly, low serum calcium and phosphate levels have been reported in COVID-19 patients suffering from severe disease (92) (93) (94) , and low 25(OH)D levels, although not reported (93, 94) , could be one potential contributing factor for such low levels. Only three studies used liquid chromatography mass spectroscopy, which may provide more accurate results, as compared to NIST standards (47, 62, 72) . The accuracy of the serum 25(OH)D cutoffs used in various studies is therefore unclear, and evidence for quality assurance protocol for assay standardization was mentioned in only three studies (52, 57, 61) .

To our knowledge, only one systematic-review and meta-analysis was published on this topic (95) . However, the authors only focused on COVID-19 severity, mortality and hospitalization, did not assess certainty of the evidence, combined studies with heterogeneous definitions of disease severity, and their conclusions are limited by considerations of reverse causality. We are unaware of any other systematic review and meta-analysis that aims to assess the impact of low serum 25(OH)D levels on additional important outcomes such as ICU admission, mechanical and non-invasive ventilation, ARDS. In addition, the strengths of our study lie in its extensive and rigorous search, outreach to investigators for missing data, granular analysis, use of accepted instruments to assess quality of studies and strength of the evidence reported, as well as scrutiny of the type of vitamin D assay used and timing of measurement of serum 25(OH)D levels in relation to COVID-19 related outcomes. We also excluded non peerreviewed articles to enhance the quality of the evidence. The quality of the research is crucial and due to the rapid dissemination of articles during the COVID-19 pandemic, it has been subjected to many flaws and weaknesses (35, 96) . This systematic review and meta-analysis therefore presents a thorough and reliable review and analysis of the available evidence, and a comprehensive overview of on-going clinical trials, based on a systematic search of the major trial registries.

In conclusion, our systematic review reveals that none of the outcomes evaluated revealed a clear and strong direction for a cause effect relationship of vitamin D status on COVID-19 health related outcomes. The evidence available to-date is insufficient to make any recommendations for high doses of vitamin D to either prevent or treat COVID-19 complications. Doses below the Upper Tolerable Level set by the IOM of 4,000 IU/day, are most prudent for now (22, 26, 84, 97) . Clear evidence-based recommendations on vitamin D supplementation, timing and dosing regimen can only be determined based on results from several on-going vitamin D randomized controlled trials on COVID-19 related health outcomes. Authors contributions: AB, MB, OEZ, MC and GEHF designed the search strategy; AB and MB screened titles, abstracts and full texts, and abstracted data from included studies; AB, MB and MR screened and abstracted data from clinical trials protocols; AB and MB performed statistical analysis; MC and GEHF provided input on statistical analysis and quality assessment; AB and MB wrote the paper; MC and GEHF provided major input on the paper; All authors read and approved the final manuscript. 

Coronavirus disease (COVID-19) pandemic. 2020

Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Severe outcomes among patients with coronavirus disease 2019 (COVID-19)-United States

Covid-19: Why are age and obesity risk factors for serious disease?

The D-side of COVID-19: musculoskeletal benefits of vitamin D and beyond

Weight loss, malnutrition, and cachexia in COVID-19: facts and numbers

COVID-19 is associated with clinically significant weight loss and risk of malnutrition, independent of hospitalisation: A post-hoc analysis of a prospective cohort study

Global prevalence and disease burden of vitamin D deficiency: a roadmap for action in low-and middleincome countries

Vitamin D insufficiency: Definition, diagnosis and management

Vitamin D and obesity

Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths

The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality

Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees North supports vitamin D as a factor determining severity

Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions

Vitamin D and the immune system

Modulation of the immune response to respiratory viruses by vitamin D

The trinity of COVID-19: immunity, inflammation and intervention

Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and J o u r n a l P r e -p r o o f Journal Pre-proof meta-analysis of individual participant data

Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of aggregate data from randomised controlled trials

Commentary: Myths and facts on vitamin D amidst the COVID-19 pandemic

The Benefits of Vitamin D Supplementation for Athletes: Better Performance and Reduced Risk of COVID-19

Preventing vitamin D deficiency during the COVID-19 pandemic: UK definitions of vitamin D sufficiency and recommended supplement dose are set too low

Guidance on Vitamin D in the Era of COVID-19 from the ASBMR

World Health Organization (WHO)

Coronavirus disease (COVID-19) pandemic. 2020

International Clinical Trials Registry Platform (ICTRP)

The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses The Ottawa Hospital Research Institute

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Cochrane Handbook for Systematic Reviews of Interventions

Patterns of COVID-19 Mortality and Vitamin D: An Indonesian Study. Available at SSRN 3585561

Factors associated with hospitalization and disease severity in a racially and ethnically diverse population of COVID-19 patients. medRxiv

Low serum 25-hydroxyvitamin D (25 [OH] D) levels in patients hospitalised with COVID-19 are associated with greater disease severity: results of a local audit of practice

Vitamin D insufficiency is prevalent in severe COVID-19. medRxiv

Vitamin D deficiency severe COVID-19: a convergence of two pandemics. medRxiv. 2020. 40. Glicio EJ. Vitamin D Level of Mild and Severe Elderly Cases of COVID-19: A Preliminary Report

Vitamin D Supplementation Could Possibly Improve Clinical Outcomes of Patients Infected with Coronavirus-2019 (COVID-19). Available at SSRN 3571484

Vitamin D status, body mass index, ethnicity and COVID-19: Initial analysis of the firstreported UK Biobank COVID-19 positive cases

Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection

Уровень 25 (ОН) D в сыворотке крови у больных COVID-19. Журнал инфектологии

Vitamin D status and outcomes for hospitalised older patients with COVID-19

Nutritional status of patients with coronavirus disease 2019 (COVID-19)

Vitamin D Deficiency and Outcome of COVID-19 Patients

Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19

Possible association of vitamin D status with lung involvement and outcome in patients with COVID-19: a retrospective study

Vitamin D 25OH deficiency in COVID-19 patients admitted to a tertiary referral hospital

Vitamin D Status in Hospitalized Patients with SARS-CoV

Impact of Serum 25(OH) Vitamin D Level on Mortality in Patients with COVID-19 in Turkey

Vitamin D Deficiency Is Inversely Associated with COVID-19 Incidence and Disease Severity in Chinese People

Examine the association between severe Vitamin D deficiency and mortality in patients with Covid-19

Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers

Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose

Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort

Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study

Serum Levels of Vitamin C and Vitamin D in a Cohort of Critically Ill COVID-19 Patients of a North American Community Hospital Intensive Care Unit in May 2020: A Pilot Study

Role of Vitamin D in Pathogenesis and Severity of Coronavirus Disease

High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study

Serum 25(OH)D Level on Hospital Admission Associated With COVID-19 Stage and Mortality

Vitamin D Status is Associated With In-hospital Mortality and Mechanical Ventilation: A Cohort of COVID-19 Hospitalized Patients

Low plasma 25 (OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study

Interaction between age and vitamin D deficiency in severe COVID-19 infection

Does Serum Vitamin D Level Affect COVID-19 Infection and Its Severity?-A Case-Control Study

Evaluation of the relationship of serum vitamin D levels in COVID-19 patients with clinical course and prognosis

Association of Vitamin D Deficiency and Treatment with COVID-19 Incidence

The Association Between the Level of Serum 25(OH) Vitamin D, Obesity, and underlying Diseases with the risk of Developing COVID-19 Infection: A case-control study of hospitalized patients in Tehran

Association of vitamin D with the modulation of the disease severity in COVID-19

Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2

Greater risk of severe COVID-19 in Black, Asian and Minority Ethnic populations is not explained by cardiometabolic, socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: study of 1326 cases from the UK Biobank

Vitamin D concentrations and COVID-19 infection in UK Biobank

Expression of Concern: Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection

Effect of Calcifediol Treatment and best Available Therapy versus best Available Therapy on Intensive Care Unit Admission and Mortality Among Patients Hospitalized for COVID-19: A Pilot Randomized Clinical study

Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study)

Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial

Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020_166

MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19

Calcitriol, the active form of vitamin D, is a promising candidate for COVID-19 prophylaxis

Vitamin D supplementation could reduce the risk of type A influenza infection and subsequent pneumonia

Vitamin D in acutely ill patients

Plasma 25-hydroxy-cholecalciferol (Vitamin D) is depressed by inflammation: implications and parallels with other micronutrients. Sight and Life

The relation between acute changes in the systemic inflammatory response and plasma 25-hydroxyvitamin D concentrations after elective knee arthroplasty. The American journal of clinical nutrition

Vitamin D in acute stress and critical illness

The When, What & How of Measuring Vitamin D Metabolism in Clinical Medicine

Letter to the Editor: Vitamin D deficiency in COVID-19: Mixing up cause and consequence

Reply to Vitamin D deficiency in COVID-19: mixing up cause and consequence

Hypocalcemia: the quest for the cause of a major biochemical feature of COVID-19

Low serum calcium and phosphorus and their clinical performance in detecting COVID-19 patients

Hypocalcemia is highly prevalent and predicts hospitalization in patients with COVID-19

Vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis

COVID-19 and misinformation: how an infodemic fuelled the prominence of vitamin D

-2 virus/COVID-19 disease

Detailed quality assessment is provided in Appendix C.1 using the New Castle-Ottawa quality scale 2 P-value not reported 3 Adjusted for age, sex, C-reactive protein, ischemic heart disease and severe pneumonia 4 Adjusted for age, sex and comorbidities 5 Adjusted for WBC, lymphocyte and albumin 6 Adjusted for obesity 7 Adjusted for age, sex, BMI, ethnicity, employment, race and comorbidities 8 Adjusted for age, sex, BMI, socioeconomic status, smoking and comorbidities 9 Adjusted for age, sex and ethnicity